Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Financing Activities (2016 - 2025)

Lexaria Bioscience's Cash from Financing Activities history spans 11 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 20.05% year-over-year to $3.5 million; the TTM value through Nov 2025 reached $5.2 million, down 59.7%, while the annual FY2025 figure was $6.0 million, 41.39% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $3.5 million at Lexaria Bioscience, up from $1.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $9.4 million in Q1 2021 and bottomed at -$121687.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $1.7 million (2023), against an average of $2.2 million.
  • The largest YoY upside for Cash from Financing Activities was 15375.06% in 2023 against a maximum downside of 986.01% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$10987.0 in 2021, then fell by 1.98% to -$11205.0 in 2022, then surged by 16337.13% to $1.8 million in 2023, then soared by 138.84% to $4.3 million in 2024, then dropped by 20.05% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Cash from Financing Activities are $3.5 million (Q4 2025), $1.7 million (Q2 2025), and $11720.0 (Q1 2025).